echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > "Medical Speed Reading Society" reduces risk by 83%! Dates of Tagrisso Treatment of Early Lung Cancer Iii Results Announced

    "Medical Speed Reading Society" reduces risk by 83%! Dates of Tagrisso Treatment of Early Lung Cancer Iii Results Announced

    • Last Update: 2020-06-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    ViaCyte has raised more than $200 million; FDA approves first tau pathology imaging drug; GlaxoSmithKline plans to produce 1 billion adjugate to support global partner vaccine development..Recently, Qinghai Provincial Health Insurance Bureau issued "on the submission of the 2020 provincial organizations centralized band procurement of drug-related data notice", published the 2020 province of Qinghai province with a volume of drug catalog, 49 varieties have 33 injection form, 3 inhalation preparations, two eye drops, the rest of the oral dosage form, injections become the main character of the Qinghai collection(Qinghai Medical Insurance Bureau) According to the Inner Mongolia Pharmaceutical Procurement Center statistics, in April 2020, the total amount of online procurement of drugs and medical supplies in Inner Mongolia was 1.126 billion yuan, an increase of 28.28% over MarchThe total amount of drug procurement was 927 million yuan, the purchase amount of medical supplies was 199 million yuan, and the purchase amount of orthopaedic medical supplies was the highest, accounting for 36%(Inner Mongolia Pharmaceutical Procurement Center) Since April, the health insurance bureau of Ganxi County, Guizhou Province, relying on the video surveillance cameraof of the original health insurance fixed-point retail pharmacy, invested more than 30 million yuan to establish a remote monitoring system covering 126 health insurance fixed-point retail pharmaciesUnder the influence of the outbreak, a number of local regulators have taken similar regulatory measures, through the Internet technology for retail pharmacies without contact remote supervisionViaCyte has announced the completion of a $27 million funding investment by Bain Capital to further advance the development of a number of drug candidates to provide potential new treatments for diabeticsThe company is understood to have already raised more than $200mBiotechnology company Monte Rosa has announced a $32.5 million round A financing to develop small molecule drugs that degrade disease-related proteins29 (UPI) nical, AstraZeneca announced the detailed results obtained by tagrisso, a third-generation EGFR inhibitor, in Phase III clinical trial ADAURAThe results showed that Tagrisso brought statistically significant and clinically significant improvements to patients' disease-free survival, and reduced the risk of recurrence or death by 83%29, Mercado, Weishi, South Korea's Celltrion Healthcare company announced that it will announce at the asco annual meeting four clinical results on merchadon PD-1 inhibitor Keytruda single drug or its combination with other drugs treatment, Keytruda is expected to become a new standard for the treatment of MSI-H colorectal cancer29, the U.SFDA announced the approval of Lilly's Tauvid intravenous agent on the marketIt is the first drug to receive FDA approval to help image tau pathology in the brainTauvid is a radiological diagnostic reagent for adult symnopsis who need to be evaluated for Alzheimer's disease29, Lilly Pharmaceuticals announced that Basaglar ® Phase III clinical study has reached the main research end point This is a 24-week clinical study of Basaglar, a longer-acting underlying insulin analogue, ® and ® effectiveness and safety in adult patients with type 1 diabetes in China (Sina Pharmaceutical News) -- The FDA has found that some metformin products contain higher levels of NDMA than the body's acceptable daily intake as prescribed by regulators, and is in contact with the company that makes the drug to initiate a drug recall At ASCO's annual meeting in 2020, Pfizer and Merck will announce the positive results of the interim analysis of JAVELIN Bladder 100, a phase 3 clinical trial compared to BSC, using the anti-PD-L1 drug Bavencio (avelumab) after receiving platinum chemotherapy In patients with PD-L1 plus, avelumab and BSC significantly extended The OS, which has not yet reached the median OS, compared to 17.1 months in the BSC group alone (Sina Pharmaceutical News) Recently, Roche announced that the European Medicines Agency has approved Ocrevus a new, shorter two-hour infusion program, twice a year for the treatment of recurrent or primary progressive multiple sclerosis Studies showed that in patients with recurrent-remission multiple sclerosis (289 cases received 2-hour infusions and 291 received regular 3.5-hour infusions), 2-hour infusions were comparable to the frequency and severity of 3.5-hour infusion-related reactions (Sina Pharmaceutical News) 29, Roche's Genetek announced the launch of tozhu sing-singh in combination with Redsewe treatment of patients with severe inpatient COVID-19 global multi-center Phase III clinical study The study, which is expected to start patient recruitment in June, plans to enroll 450 patients in the United States, Canada and Europe GlaxoSmithKline announced Tuesday that it plans to produce 1 billion doses of the Pandemic Vaccine Adjorizer System by 2021 to support the development of a number of new coronavirus candidates using adjuvants Adjastosants reduce the amount of viral protein in each dose of vaccine, resulting in more doses of the vaccine and a stronger, more durable immune response GlaxoSmithKline recently announced that the U.S FDA has granted it a priority review of a supplemental biologics license application, which seeks approval for the anti-inflammatory drug Nucala for the treatment of patients with high acidophilic syndrome HES is a rare, life-threatening disease caused by eosinophilic inflammation, and current treatment options are limited (Biological Valley) Recently, Pfizer submitted a clinical application for PF-06801591 injections to be accepted by CDE, the first clinically declared bhenothelidemto in China The clinical results of Phase I showed that PF-06801591 showed anti-tumor activity in a variety of tumor types every 4 weeks compared to intravenous injections every 3 weeks, and was well tolerated, with no serious skin toxicity effects found Novartis has released the latest data from the sub-group analysis of MonaLEESA-3 and MONALEESA-7 The results showed that in the MONALEESA-7 study, the Kisqali Joint Endocrine Therapy group had a 30% lower risk of death compared to patients in the group who used endocrine therapy alone, and patients in the MONALEESA-3 study had a 20% lower risk of death Iovance (PharmaCope) has announced the latest results for TIL therapy lifileucel treatment for patients with advanced melanoma: one injection of lifileucel, which provides an overall remission rate of 34.3 percent in patients who have received PD-1 inhibitors and BRAF/MEK targeted therapy The data will support the company's application for a biologics license to the U.S FDA this year Stone Pharmaceutical Group announced that its class 1 new drug SYHA1805 tablets have been approved by the State Drug Administration to conduct clinical trials in China for use in non-alcoholic fatty hepatitis The product is a new type of small molecular agonisant, there is no similar products listed in the world (Sina Pharmaceutical News) Genmab announced that its CD38 antibody daratumab, developed with Jansen, reached the main end of the study in THE phase 3 clinical study OF ANDROMEDA in the treatment of newly confirmed immunoglobulin light chain amyloid degeneration patients with combined cyclophosphamide, boratizomi and dexametsulm (Pharma Mingcond) and Huang Pharma announced on the 29th that the State Drug Administration has accepted the application of volitinib for the treatment of non-small cell lung cancer of interstitial epithelial conversion factor (MET) extralmal 14 jump, which is The first listing application of Volitinib in the world In clinical studies of more than 1,000 patients worldwide, Volitinib has shown good clinical outcomes in a variety of tumors with MET gene abnormalities (Sina Pharmaceutical News) Green Leaf Pharmaceuticals declared Liss's clear-skinned paste in the domestic listing application in the "in approval" status, is expected to be approved soon to be approved for the treatment of mild moderate Alzheimer's disease The journal Science has published a new paper on cancer research The team, led by the Weizmann Institute of Science in Israel, found that there are many bacteria in human tumors, with different tumor samples and different types of bacteria This work is important for understanding the microbiome of tumors (Academic) Recently, Nature published the "Cancer Cell Therapy: Prospects for Clinical Trials" 2020 report, which shows that the field of cell immunotherapy continues to expand, as of March, the global cancer cell therapy pipeline includes 1,483 active therapies The Report shows that the United States and China dominate the cancer cell treatment research and development pipeline, with 600 in the U.S as of March 2020, followed by China with 508 (Pharmaceutical Intelligence Network)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.